Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor

A technology of HIF-1 and HIF-2, which can be used in medical preparations, drug combinations, genetic material components, etc. containing active ingredients, and can solve problems such as unreported

Active Publication Date: 2010-10-20
SENJU PHARMA CO LTD
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Currently, it has been reported that siRNA or antisense of HIF-1α is used as a therapeutic drug for age-related macular degeneration or diabetic retinopathy (refer to Patent Documents 1-3), but the use of siRNA and antisense of HIF-2α is not known in the present inventors. As far as we know, there are no reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor
  • Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor
  • Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0130] Examples are given below to further describe the present invention in detail, but the present invention is not limited thereto.

preparation example 1

[0131] Preparation example 1: Injection for intravitreal administration

[0132] Injections for intravitreal administration shown below were prepared according to conventional methods.

[0133] HIF-1α siRNA:

[0134] Sense-GGA ACC UGA UGC UUU AAC UTT (SEQ ID NO.5) 1mg

[0135] Antisense-AGU UAA AGC AUC AGG UUC CTT (SEQ ID NO.11) 1mg

[0136] HIF-2α siRNA:

[0137] Sense-CGG AGG UGU UCU AUG AGC UTT (SEQ ID NO.9) 1mg

[0138] Antisense-AGC UCA UAG AAC ACC UCC GTC (SEQ ID NO.15) 1mg

[0139] Sodium dihydrogen phosphate 0.1g

[0140] Sodium chloride 0.9g

[0141] Appropriate amount of sodium hydroxide

[0142] Appropriate amount of sterile purified water

[0143]

[0144] Total 100mL

[0145] (pH7)

preparation example 2

[0146] Formulation example 2: Injection for intravitreal administration

[0147] Injections for intravitreal administration shown below were prepared according to conventional methods.

[0148] HIF-1α siRNA:

[0149] Sense-GGG UAA AGA ACA AAA CAC A TT (SEQ ID NO.6) 0.1mg

[0150] Antisense - UGU GUU UUG UUC UUU ACC C TT (SEQ ID NO.12) 0.1mg

[0151] HIF-2α siRNA:

[0152] Sense-GGU UUU GUU GCU AGC CCU U TT (SEQ ID NO.10) 0.1mg

[0153] Antisense-AAG GGC UAG CAA CAA AAC C TT (SEQ ID NO.16) 0.1mg

[0154] Sodium dihydrogen phosphate 0.1g

[0155] Glycerin 2.5g

[0156] Appropriate amount of sodium hydroxide

[0157] Appropriate amount of sterile purified water

[0158]

[0159] Total 100mL

[0160] (pH 7)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

It is intended to provide a pharmaceutical product with a high therapeutic effect in the treatment of a retinal disease accompanied by angiogenesis such as age-related macular degeneration or diabetic retinopathy. A therapeutic agent for a retinal disease containing a substance that specifically inhibits the expression of HIF-1alpha and a substance that specifically inhibits the expression of HIF-2alpha. The inhibitor which is an active ingredient of the therapeutic agent of the invention is an RNAi-inducible nucleic acid, an antisense nucleic acid, or a ribozyme against HIF-1a and HIF-2a, or an expression vector therefor.

Description

technical field [0001] The present invention relates to medicaments containing HIF-1α and HIF-2α expression inhibitory substances. Specifically, it relates to a therapeutic agent for retinal diseases containing a nucleic acid capable of inducing RNA interference. Background technique [0002] Hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2) are heterodimers containing α and β subunits that share a basic helix-loop-helix (bHLH) domain and a PAS domain transcription factor. The expression and transcriptional activity of HIF increased significantly when the intracellular oxygen concentration decreased. Target genes transactivated by HIF have been identified including genes encoding VEGF (vascular endothelial growth factor), erythropoietin, glucose transporter, and glycolytic enzymes (see Non-Patent Document 1). [0003] Diabetic retinopathy and age-related macular degeneration are diseases that cause acquired blindness, and the development of drugs for inhibiting neovascu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/7088A61K31/7105A61K31/713A61K35/76A61K48/00A61P3/10A61P27/02A61P37/06A61P43/00C12N15/00C12N15/113
CPCA61K45/06C12N2310/14A61K31/7105A61K31/7088C12N15/1136A61K31/713C12N15/113C12N2310/11A61P27/02A61P37/06A61P43/00A61P3/10
Inventor 中岛毅中岛惠美东光佳
Owner SENJU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com